Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. ABL Diagnostics's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was €0.00 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.
ABL Diagnostics (XPAR:ABLD) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
ABL Diagnostics Selling, General, & Admin. Expense Related Terms
ABL Diagnostics Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics Selling, General, & Admin. Expense Chart
XPAR:ABLD vs VEEV, BTSG, HQY: Selling, General, & Admin. Expense Comparison
For the Health Information Services subindustry, ABL Diagnostics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Selling, General, & Admin. Expense vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Selling, General, & Admin. Expense falls into.
ABL Diagnostics Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of €0.00 Mil mean?
ABL Diagnostics (XPAR:ABLD) has a Selling, General, & Admin. Expense of €0.00 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ABL Diagnostics and its competitors.
Is ABL Diagnostics' Selling, General, & Admin. Expense too high?
ABL Diagnostics' current Selling, General, & Admin. Expense is €0.00 Mil. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Selling, General, & Admin. Expense compare to VEEV and BTSG?
ABL Diagnostics' Selling, General, & Admin. Expense of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Healthcare Providers & Services company?
A good Selling, General, & Admin. Expense depends on the Healthcare Providers & Services industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Selling, General, & Admin. Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.00, compared to a current price of €2.42 — trading 69.8% below its estimated fair value. The current Selling, General, & Admin. Expense is €0.00 Mil. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Selling, General, & Admin. Expense is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.42 is trading 69.8% below its estimated GF Value™ of €8.00.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Selling, General, & Admin. Expense: €0.00 Mil
GF Value™: €8.00 vs. price of €2.42 (69.8% below fair value)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
